Merit Medical Systems (NASDAQ:MMSI) Ticks All The Boxes When It Comes To Earnings Growth
Merit Medical Systems (NASDAQ:MMSI) Ticks All The Boxes When It Comes To Earnings Growth
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad.
一些投机者对于能够扭转乾坤的公司投资的兴奋是巨大的吸引力,所以即使是没有营业收入、没有盈利并且一直做不到期望的公司也可以找到投资者。不幸的是,这些高风险的投资往往几乎没有可能有所回报,许多投资者会为此付出代价。亏损的公司可能就像资本的海绵一样,投资者应该谨慎,以免把好钱投向投机。
If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Merit Medical Systems (NASDAQ:MMSI). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Merit Medical Systems with the means to add long-term value to shareholders.
如果这种公司不是你的菜,你更喜欢能够产生营业收入甚至盈利的公司,那么你可能会对美泰医疗系统(纳斯达克股票代码:MMSI)产生兴趣。即使这家公司已经被市场合理地评估,但投资者会认为,持续赚取稳定的利润将继续为美泰医疗系统提供增加股东长期价值的方式。
How Fast Is Merit Medical Systems Growing Its Earnings Per Share?
美泰医疗系统的每股收益增长速度有多快?
Over the last three years, Merit Medical Systems has grown earnings per share (EPS) at as impressive rate from a relatively low point, resulting in a three year percentage growth rate that isn't particularly indicative of expected future performance. As a result, we'll zoom in on growth over the last year, instead. Merit Medical Systems' EPS has risen over the last 12 months, growing from US$1.49 to US$1.75. There's little doubt shareholders would be happy with that 18% gain.
在过去三年中,美泰医疗系统从一个相对较低的点开始,以非常出色的速度提高了每股收益(EPS),导致三年的年均百分比增长率并不特别表明未来的表现。因此,我们将转而关注最近一年的增长。美泰医疗系统的每股收益在过去的12个月间增长了,从1.49美元增长到1.75美元,股东对这18%的增长应该感到满意。
Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. EBIT margins for Merit Medical Systems remained fairly unchanged over the last year, however the company should be pleased to report its revenue growth for the period of 9.4% to US$1.3b. That's progress.
仔细考虑营业收入增长和利润前利息、税、折旧和摊销(EBIT)毛利率可以帮助你对最近的利润增长的可持续性有一个全面的了解。美泰医疗系统的EBIT毛利率在过去一年里基本不变,但该公司应该对该期的营业收入增长9.4%至13亿美元的报告感到满意。这是一个进步。
The chart below shows how the company's bottom and top lines have progressed over time. For finer detail, click on the image.
下图显示了该公司底线和顶线随着时间的推移而发展的情况。点击图片以获取更精细的详细信息。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240718/0-d47e27a3f4362196f608dbd0f8f6f389-0-4cb93a08a838d2839426691b65297926.png/big)
While we live in the present moment, there's little doubt that the future matters most in the investment decision process. So why not check this interactive chart depicting future EPS estimates, for Merit Medical Systems?
虽然我们活在当下,但毫无疑问未来在投资决策过程中最为重要。那么不妨查看一下这份交互式图表,其中包含针对美泰医疗系统的未来每股收益预测吧。
Are Merit Medical Systems Insiders Aligned With All Shareholders?
美泰医疗系统的内部人员是否与所有股东保持一致?这应该让投资者对持有该公司的股票有一定的安全感,因为内部人员持有股票意味着他们的利益与公司的利益密切相关。股东将会为内部人员持有美泰医疗系统股票达到价值相当的事实感到高兴。我们注意到他们在该公司的持股量值1.16亿美元。投资者将欣赏管理团队拥有如此数量的股份,因为它显示了他们对公司未来的承诺。
It should give investors a sense of security owning shares in a company if insiders also own shares, creating a close alignment their interests. Shareholders will be pleased by the fact that insiders own Merit Medical Systems shares worth a considerable sum. We note that their impressive stake in the company is worth US$116m. Investors will appreciate management having this amount of skin in the game as it shows their commitment to the company's future.
你是否应该将美泰医疗系统加入自选股?美泰医疗系统的一个亮点是其每股收益正在增长,这很不错。如果仅凭这一点还不足以说服你,还有相当引人注目的内部股权水平。这两个因素都是公司的亮点,应该成为你自选股的有力竞争者。现在,你可以通过关注这些因素来做出关于美泰医疗系统的决定,或者你还可以考虑它的市盈率与行业其他公司的比较。
Should You Add Merit Medical Systems To Your Watchlist?
你是否应该将美泰医疗系统加入自选股?美泰医疗系统的一个亮点是其每股收益正在增长,这很不错。如果仅凭这一点还不足以说服你,还有相当引人注目的内部股权水平。这两个因素都是公司的亮点,应该成为你自选股的有力竞争者。现在,你可以通过关注这些因素来做出关于美泰医疗系统的决定,或者你还可以考虑它的市盈率与行业其他公司的比较。
One positive for Merit Medical Systems is that it is growing EPS. That's nice to see. If that's not enough on its own, there is also the rather notable levels of insider ownership. These two factors are a huge highlight for the company which should be a strong contender your watchlists. Now, you could try to make up your mind on Merit Medical Systems by focusing on just these factors, or you could also consider how its price-to-earnings ratio compares to other companies in its industry.
美泰医疗系统的一个优点是正在增长每股收益,这是件好事。如果仅凭这一点还不足以让你有所决定,还有一个相当值得注意的内部股权水平。这两个因素都是公司的亮点,应该成为你自选股票的有力竞争者。现在,你可以仅考虑这些因素来做出关于在关注美泰医疗系统的决定,或者你也可以考虑一下它的市盈率与同行业其他公司的比较。
While opting for stocks without growing earnings and absent insider buying can yield results, for investors valuing these key metrics, here is a carefully selected list of companies in the US with promising growth potential and insider confidence.
虽然选择不断增长的收益并且没有内部买入的股票将会产生结果,但对于评估公司的关键指标价值的投资者来说,这是一个仔细挑选的在美国有潜在增长和内部信心的公司列表。
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
请注意,本文讨论的内部交易是指在相关司法管辖区中报告的交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?对内容感到担忧?请直接与我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?对内容感到担忧?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。